Elicio Therapeutics

Elicio (Nasdaq: $ELTX) is advancing a pipeline of novel lymph node-targeted immunotherapies for the treatment of some of the most aggressive cancers.

[Elicio Therapeutics @ElicioTx]

Today we’re presenting late-breaking results from our Phase 2 AMPLIFY-7P study evaluating camupepimut (ELI-002 7P) in patients with resected pancreatic cancer at #ESMO26, as well as in a Nature Medicine publication. Read more about the study results here: https://t.co/OiJyopcFdq

[Elicio Therapeutics @ElicioTx]

New pre-specified Phase 2 analyses highlight the clinical potential of ELI-002 7P (camupepimut) in adjuvant pancreatic cancer and are expected to help shape the Company’s Phase 3 development strategy. Read more: https://t.co/Mp8XwijAYx #ESMO26 $ELTX

[Elicio Therapeutics @ElicioTx]

“We are pleased to share the complete AMPLIFY-7P results, including new late-breaking analyses, with the global oncology community at ESMO Congress 2026,” said Robert Connelly, President and Chief Executive Officer of Elicio. Read more: https://t.co/Mp8XwijAYx $ELTX #ESMO26

[Elicio Therapeutics @ElicioTx]

New pre-specified analyses from the randomized Ph.2 AMPLIFY-7P study of ELI-002 7P in resected PDAC have been selected for a late-breaking Proffered Paper oral presentation at the #ESMO26 Congress, being held October 23–27, 2026, in Madrid. https://t.co/Mp8XwijAYx $ELTX

[Elicio Therapeutics @ElicioTx]

Elicio will be available for one-on-one meetings at the Wells Fargo 21st Annual Healthcare Conference on Thursday, September 10th. Read more: https://t.co/arCXGjlnBF $ELTX

[Elicio Therapeutics @ElicioTx]

Elicio today announced that Robert Connelly, CEO and Pete DeMuth, PhD, Chief Scientific Officer, will participate in a fireside chat at the upcoming @HCWCO 28th Annual Global Investment Conference on Monday, Sept. 14th at 2pm ET. https://t.co/8itTRcPh81 $ELTX

[Elicio Therapeutics @ElicioTx]

Elicio today announced that management will participate in one-on-one meetings at the upcoming Wells Fargo 21st Annual Healthcare Conference, taking place September 8-10, 2026, in Boston, MA. For more details, visit: https://t.co/arCXGjlnBF $ELTX

[Elicio Therapeutics @ElicioTx]

Following multiple complete responses, Elicio plans to initiate a Ph. 1 combo. study of ELI-002 7P plus a RAS inhibitor, with or without an anti-PD-1 inhibitor, in metastatic pancreatic cancer in Q4 2026. Read CEO Robert Connelly’s comments: https://t.co/SCbauq5ApW $ELTX

[Elicio Therapeutics @ElicioTx]

Elicio today reported financial results for the quarter ended June 30, 2026, and provided recent corporate and clinical updates. Read more: https://t.co/SCbauq5ApW $ELTX

[Elicio Therapeutics @ElicioTx]

“The activation of this study marks an important milestone as we prepare to evaluate the potential of ELI-002 7P across multiple stages of pancreatic cancer,” said Christopher Haqq, M.D., Ph.D., VP, Head of R&D and CMO. Read more about the study: https://t.co/DsytBAE4Wr $ELTX

[Elicio Therapeutics @ElicioTx]

Elicio today announced the opening of the investigator-initiated (“IIT”) Phase 1 neoadjuvant study evaluating ELI-002 7P in combination with chemotherapy and an anti-PD1 checkpoint inhibitor in borderline resectable and resectable PDAC.

The study, conducted by @MSKCancerCenter and funded through a strategic partnership between @lustgartenfdn and @BreakthroCancer is expected to enroll 20 patients. Read more: https://t.co/XKJIb63P3O $ELTX

[Elicio Therapeutics @ElicioTx]

“Inclusion of Elicio Therapeutics in the Russell 2000® and Russell 3000® Indexes is a meaningful milestone that reflects the growing recognition of the Company’s progress,” said Robert Connelly, CEO of Elicio Therapeutics. Read more: https://t.co/IQ3na0oYAx $ELTX

[Elicio Therapeutics @ElicioTx]

Elicio Therapeutics today announced that the Company was added to the Russell 2000® and Russell 3000® Indexes, effective after the U.S. market close on June 26, 2026, as part of the 2026 Russell indexes annual reconstitution. Learn more: https://t.co/IQ3na0oYAx $ELTX

[Elicio Therapeutics @ElicioTx]

Tune-in soon for a virtual @ElicioTx KOL event today, June 24 at 1 PM ET. Experts will discuss complete radiographic and metabolic responses in patients from the Phase 2 AMPLIFY-7P study who received nivolumab-based subsequent therapy. Join here: https://t.co/G73BOGoO0E $ELTX

[LifeSci Advisors @LifeSciAdvisors]

Join @ElicioTx $ELTX for a virtual KOL event on June 24 at 1pm ET to discuss complete radiographic and metabolic responses in patients who progressed on ELI-002 7P in the Phase 2 AMPLIFY-7P study and later received nivolumab-based therapy.

Register: https://t.co/NrbJpjIq3m

[Elicio Therapeutics @ElicioTx]

Elicio will host a virtual KOL event on Wednesday, June 24th, at 1 PM ET. Company management will be joined by Peter Hosein, M.D., Professor of Clinical Medicine, Sylvester Comprehensive Cancer Center, University of Miami, and Zev Wainberg, M.D., Professor of Medicine at UCLA and co-director of the UCLA GI Oncology Program. Register here: https://t.co/JrfhcDTYXD $ELTX

[Elicio Therapeutics @ElicioTx]

"Three complete responses observed following subsequent nivolumab-based therapy are particularly intriguing because complete, durable tumor responses in this setting are historically rare," said Robert Connelly, $ELTX President and CEO. Learn more about the reported preliminary clinical observations: https://t.co/1klovIlIGH

[Elicio Therapeutics @ElicioTx]

"The observations reported today provide a compelling rationale for a Phase 1 study evaluating ELI-002 7P in combination with checkpoint inhibition and standard therapy in metastatic pancreatic cancer," said Christopher Haqq, M.D., Ph.D., Executive Vice President, Head of Research and Development and Chief Medical Officer of Elicio. Read more: https://t.co/1klovIlIGH $ELTX

[Elicio Therapeutics @ElicioTx]

Elicio Therapeutics reported preliminary clinical observations which the Company believes support the evaluation of ELI-002 7P in combination with checkpoint inhibition. The Company also announced plans to conduct a Phase 1 study in first-line metastatic mKRAS PDAC, subject to funding. If validated by a Phase 1 study, activity in metastatic PDAC may allow a rapid development pathway for ELI-002 7P and inform the design of the future Phase 3 trial in adjuvant PDAC. Read more: https://t.co/1klovIlIGH $ELTX

[Elicio Therapeutics @ElicioTx]

Elicio Therapeutics today reported results from its randomized Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with adjuvant mKRAS-driven pancreatic ductal adenocarcinoma following completion of standard locoregional therapy. Elicio will host a conference call today, Monday, June 15th at 8:30 AM ET, for details: https://t.co/bCgQDJifYo $ELTX